JPH08266587A - Eyedrop container - Google Patents
Eyedrop containerInfo
- Publication number
- JPH08266587A JPH08266587A JP7072871A JP7287195A JPH08266587A JP H08266587 A JPH08266587 A JP H08266587A JP 7072871 A JP7072871 A JP 7072871A JP 7287195 A JP7287195 A JP 7287195A JP H08266587 A JPH08266587 A JP H08266587A
- Authority
- JP
- Japan
- Prior art keywords
- container
- polyolefin
- eyedrop
- subjected
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 36
- 229920000098 polyolefin Polymers 0.000 claims abstract description 18
- 229920000728 polyester Polymers 0.000 claims abstract description 10
- 229920000515 polycarbonate Polymers 0.000 claims abstract description 9
- 239000004417 polycarbonate Substances 0.000 claims abstract description 9
- 238000004132 cross linking Methods 0.000 claims abstract description 8
- -1 polyethylene Polymers 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 229940079593 drug Drugs 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 10
- 238000003682 fluorination reaction Methods 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 239000011261 inert gas Substances 0.000 abstract description 3
- 229910052731 fluorine Inorganic materials 0.000 abstract description 2
- 239000011737 fluorine Substances 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000008246 gaseous mixture Substances 0.000 abstract 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 2
- 229960004475 chlortetracycline Drugs 0.000 description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 2
- 235000019365 chlortetracycline Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 description 2
- 229960002253 neostigmine methylsulfate Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005672 polyolefin resin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、点眼液中の薬物の吸着
を起こさない点眼容器に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an eye drop container which does not cause a drug in an eye drop to be adsorbed.
【０００２】[0002]
【従来の技術】点眼液には種々の薬物が配合されてお
り、このような点眼液をポリオレフィン製の点眼容器に
入れて保存すると、点眼液中の薬物のいくつかは点眼容
器に吸着されるので、薬物吸収性のないポリエステルや
ポリカーボネート製の点眼容器に点眼液を入れて保存す
ることが好ましい。しかし、ポリエステルやポリカーボ
ネートはポリオレフィンに比べて成形性が劣るという欠
点があるため、容器本体にポリエステルやポリカーボネ
ートを用い、中栓部のみポリオレフィンとするのが一般
的である。しかしこの場合も中栓のポリオレフィンに薬
物が吸着するため、表面にフッ素化層を形成したポリオ
レフィン製の中栓を有する点眼容器が考案されている
（実公平４−４８１８９号公報）。2. Description of the Related Art Various drugs are mixed in eye drops, and when such drops are stored in a polyolefin eye drop container, some of the drugs in the eye drop are adsorbed in the eye drop container. Therefore, it is preferable to store the eye drops in a eye drop container made of polyester or polycarbonate having no drug absorbability. However, polyesters and polycarbonates have a drawback that they are inferior in moldability to polyolefins. Therefore, it is common to use polyesters or polycarbonates for the container body and use only the inside plugs as polyolefins. However, also in this case, since the drug is adsorbed to the polyolefin having the inner stopper, an eye drop container having a polyolefin inner stopper having a fluorinated layer formed on the surface has been devised (Japanese Utility Model Publication No. 4-48189).
【０００３】[0003]
【発明が解決しようとする課題】しかしながら、従来の
技術ではまだ点眼液中の薬物の吸着の抑制が充分とはい
えなかった。However, it cannot be said that the conventional techniques have sufficiently suppressed the adsorption of the drug in the eye drop.
【０００４】[0004]
【課題を解決するための手段】本発明者らは鋭意研究の
結果、ポリオレフィンの表面に架橋処理を施した後、フ
ッ素化処理を施したポリオレフィン製の中栓を有する、
ポリエステルまたはポリカーボネート製の点眼容器が前
記課題を解決することを見いだした。本発明において、
ポリオレフィンとは、ポリエチレン、ポリプロピレンな
どである。Means for Solving the Problems As a result of earnest research by the present inventors, the present invention has a polyolefin inner plug which is fluorinated after a crosslinking treatment is applied to the surface of the polyolefin.
It has been found that an eye drop container made of polyester or polycarbonate solves the above problems. In the present invention,
Polyolefin is polyethylene, polypropylene, or the like.
【０００５】本発明の点眼容器に入れて保存する点眼液
に配合する成分としては、目の疾病治療、機能の回復、
使用感の改善を目的とする薬物（抗生物質：テトラサイ
クリン、クロルテトラサイクリン、オーレオマイシン、
ストレプトマイシン、クロラムフェニコールなど 抗菌
薬：スルファメトキサゾール、スルフイソキサゾール及
びそのナトリウム塩など 抗ヒスタミン薬：塩酸ジフェ
ンヒドラミン、マレイン酸クロルフェニラミンなど 抗
炎症薬：水溶性アズレン、グアイアズレン、コーチゾ
ン、グリチルリチン酸ジカリウムなど ビタミン：ビタ
ミンＢ2、ビタミンＢ6、ビタミンＢ12、ビタミンＣ、ビ
タミンＥなど 目の調節機能改善薬：メチル硫酸ネオス
チグミンなど 収れん薬：硫酸亜鉛、ホウ酸など 清涼
薬：ｌ−メントール、dl−ボルネオール、dl−カンフル
など）などである。これらの薬物の１種または２種以上
を配合した点眼液を本発明による点眼容器に入れて保存
すると薬物の吸着量が著しく少なく、点眼液の効力の低
下を起こさない。The components to be added to the eye drops to be stored in the eye drop container of the present invention include treatment of eye diseases, restoration of function,
Drugs aimed at improving the feeling of use (antibiotics: tetracycline, chlortetracycline, aureomycin,
Streptomycin, chloramphenicol, etc. Antibacterial drug: sulfamethoxazole, sulfisoxazole and its sodium salt, etc. Antihistamine: diphenhydramine hydrochloride, chlorpheniramine maleate, etc. Anti-inflammatory drug: water-soluble azulene, guaiazulene, cortisone , Dipotassium glycyrrhizinate, etc. Vitamin: vitamin B 2 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin E, etc. Eye regulators: neostigmine methyl sulfate, etc. Astringent: zinc sulfate, boric acid, etc. Cooling agent: l- Menthol, dl-borneol, dl-camphor, etc.) and the like. When an eye drop containing one or more of these drugs is stored in the eye drop container of the present invention for storage, the amount of the drug adsorbed is remarkably small and the efficacy of the eye drop does not decrease.
【０００６】[0006]
【実施例】以下、図面に基づいて本発明を説明する。図
１は、本発明の一実施態様を示す点眼容器の先端部の斜
視図である。図２は、図１に示す点眼容器先端部の縦断
面図である。本発明の点眼容器は、表面に架橋処理及び
フッ素化処理を行ったポリオレフィン製の中栓１をポリ
エステルまたはポリカーボネート製の容器本体に装着し
た点眼容器である。DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described below with reference to the drawings. FIG. 1 is a perspective view of a tip portion of an eyedrop container showing an embodiment of the present invention. FIG. 2 is a vertical cross-sectional view of the tip part of the eye drop container shown in FIG. The eyedrop container of the present invention is an eyedrop container in which a polyolefin inner plug 1 whose surface is cross-linked and fluorinated is attached to a container body made of polyester or polycarbonate.
【０００７】本発明において、中栓１は、点眼容器の点
滴部に通常用いられる形状や構造で差し支えないが、ポ
リオレフィン本来の柔軟性を失わない程度にその表面の
み架橋処理及びフッ素化処理が施されている。中栓１
は、ポリオレフィンを用いて所望の形状や構造に成形し
た後、ケーシングの技術（R.H.Hansen，J.Polym.sci.，
Ｂ，4巻，203〜209ページ，1966年）を用いて表面に架
橋処理を行った後、気密容器に入れ室温〜200℃でフッ
素ガスと不活性ガスの混合ガスを適当時間作用させて表
面をフッ素化処理することにより製造される。In the present invention, the inner plug 1 may have a shape or structure usually used for an infusion part of an eye drop container, but its surface is subjected to a crosslinking treatment and a fluorination treatment to the extent that the original flexibility of the polyolefin is not lost. Has been done. Inner stopper 1
After molding into the desired shape and structure using polyolefin, the casing technology (RHHansen, J.Polym.sci.,
B, Vol. 4, pp. 203-209, 1966), after cross-linking the surface, put it in an airtight container and allow a mixed gas of fluorine gas and inert gas to act for a suitable time at room temperature to 200 ° C. Is produced by fluorinating.
【０００８】このようにして製造した中栓１を、ポリエ
ステルまたはポリカーボネート製の容器本体に常用手段
により装着して本発明の点眼容器を組み立てる。なお、
ケーシングとは、ヘリウムのような不活性ガスを放電過
程により活性化し、これをポリオレフィン樹脂表面に衝
突させることにより、表面より水素を放出させ、ラジカ
ル化した炭素同士を結合させる方法である。The thus-prepared inner stopper 1 is attached to a polyester or polycarbonate container body by a conventional means to assemble the eye drop container of the present invention. In addition,
The casing is a method in which an inert gas such as helium is activated by a discharge process and collides with the surface of a polyolefin resin to release hydrogen from the surface and bond radicalized carbons.
【０００９】[0009]
処 方 メチル硫酸ネオスチグミン ３ｍｇ マレイン酸クロルフェニラミン ２０ｍｇ クロロブタノール ２５０ｍｇ ｌ−メントール ４０ｍｇ dl−ボルネオール １０ｍｇ dl−カンフル ５ｍｇ ホウ酸 １５００ｍｇ ホウ砂 １００ｍｇ ニッコールＨＣＯ６０ １５０ｍｇ （ポリオキシエチレンヒマシ油誘導体日本サーフアクタ
ント工業社製） 塩化ベンザルコニウム １０ｍｇ 滅菌精製水 全１００ｍｌ 上記処方に従い、常法により点眼液を調製した。ポリエ
ステル製容器本体に架橋及びフッ素処理を施したポリエ
チレン製筒状点滴部を装着した本発明点眼容器と前記容
器本体に未処理ポリエチレン製筒状点滴部を装着した対
照点眼容器を用意し、これらに前記点眼液を入れ、点滴
部を下にして４０℃の恒温槽内に保存し、点眼液中のｌ
−メントールの量をガスクロマトグラフィーにより経時
的に測定した。Method: Neostigmine methylsulfate 3 mg Chlorpheniramine maleate 20 mg Chlorobutanol 250 mg l-Menthol 40 mg dl-borneol 10 mg dl-camphor 5 mg Boric acid 1500 mg Borax 100 mg Nikkor HCO60 150 mg (Polyoxyethylene castor oil derivative Japan Surfactant Co., Ltd. ) Benzalkonium chloride 10 mg Sterile purified water Total 100 ml According to the above formulation, an eye drop was prepared by a conventional method. A polyester eye drop container of the present invention equipped with a cross-linked and fluorinated polyethylene tubular drip part and a control eye drop container equipped with an untreated polyethylene tubular drip part of the container body are prepared. The above eye drop was put in and stored in a constant temperature bath at 40 ° C. with the drip part facing down.
-The amount of menthol was measured by gas chromatography over time.
【００１０】ガスクロマトグラフ測定条件 機種：島津製作所製ＧＣ−１４Ｂ 検出器：水素炎イオン化検出器 カラム：液層ポリエチレングリコール ０．５３ｍｍ×
２５ｍ カラム温度：１１０℃ キャリヤーガス：Ｈｅ その結果を表１に示す。Gas chromatographic measurement conditions Model: Shimadzu Corporation GC-14B Detector: Hydrogen flame ionization detector Column: Liquid layer polyethylene glycol 0.53 mm x
25 m Column temperature: 110 ° C. Carrier gas: He The results are shown in Table 1.
【００１１】[0011]
【表１】 [Table 1]
図１は、本発明の一実施態様を示す点眼容器の先端部の
斜視図である。図２は、図１に示す点眼容器先端部の縦
断面図である。図において、１は中栓、２は容器本体を
示す。FIG. 1 is a perspective view of a tip portion of an eyedrop container showing an embodiment of the present invention. FIG. 2 is a vertical cross-sectional view of the tip part of the eye drop container shown in FIG. In the figure, 1 is an inner stopper and 2 is a container body.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 漆崎 文男 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Fumio Urushizaki 3-24-1 Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd.
Claims (3)
たポリオレフィンを中栓に用いたことを特徴とするポリ
エステルまたはポリカーボネート製の点眼容器。1. An eyedrop container made of polyester or polycarbonate, characterized in that a polyolefin whose surface is crosslinked and fluorinated is used as an inner stopper.
請求項１に記載の点眼容器。2. The polyolefin is polyethylene.
The eye drop container according to claim 1.
項１に記載の点眼容器。3. The eyedrop container according to claim 1, wherein the crosslinking treatment is casing treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7072871A JPH08266587A (en) | 1995-03-30 | 1995-03-30 | Eyedrop container |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7072871A JPH08266587A (en) | 1995-03-30 | 1995-03-30 | Eyedrop container |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH08266587A true JPH08266587A (en) | 1996-10-15 |
Family
ID=13501826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7072871A Pending JPH08266587A (en) | 1995-03-30 | 1995-03-30 | Eyedrop container |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH08266587A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013129318A1 (en) * | 2012-02-27 | 2013-09-06 | ロート製薬株式会社 | Ophthalmic composition kit |
| WO2016139943A1 (en) * | 2015-03-02 | 2016-09-09 | 東洋製罐グループホールディングス株式会社 | Nozzle |
-
1995
- 1995-03-30 JP JP7072871A patent/JPH08266587A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013129318A1 (en) * | 2012-02-27 | 2013-09-06 | ロート製薬株式会社 | Ophthalmic composition kit |
| JP2013213052A (en) * | 2012-02-27 | 2013-10-17 | Rohto Pharmaceutical Co Ltd | Ophthalmic composition kit |
| JP2013213053A (en) * | 2012-02-27 | 2013-10-17 | Rohto Pharmaceutical Co Ltd | Ophthalmic composition kit |
| JP5345743B1 (en) * | 2012-02-27 | 2013-11-20 | ロート製薬株式会社 | Ophthalmic composition kit |
| CN104136019A (en) * | 2012-02-27 | 2014-11-05 | 日本乐敦制药株式会社 | Ophthalmic composition kit |
| WO2016139943A1 (en) * | 2015-03-02 | 2016-09-09 | 東洋製罐グループホールディングス株式会社 | Nozzle |
| EP3266725A4 (en) * | 2015-03-02 | 2018-12-05 | Toyo Seikan Group Holdings, Ltd. | Nozzle |
| CN109625582A (en) * | 2015-03-02 | 2019-04-16 | 东洋制罐集团控股株式会社 | Nozzle |
| CN109625582B (en) * | 2015-03-02 | 2020-04-28 | 东洋制罐集团控股株式会社 | Nozzle with a nozzle body |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2396598T3 (en) | Preparations in the form of aqueous suspensions | |
| CA2190485C (en) | Lacrimal gland specific emulsions for topical application to ocular tissue | |
| DE69111821D1 (en) | ACTIVE SUBSTANCE DELIVERY VEHICLE SUSPENDED IN A NON-AQUE PERFLUORED CARRIER MEDIUM. | |
| WO2005011813A3 (en) | Treatment of ocular disease | |
| ES2109493T3 (en) | GALLENIC FORM FOR EYE ADMINISTRATION AND PREPARATION PROCEDURE. | |
| ZA200604016B (en) | Method for making pharmaceutical multiparticulates | |
| US5667799A (en) | Method for treating headache pain with topical local anesthetic compositions | |
| AU7949294A (en) | Pernasal composition and pernasal preparation containing thesame | |
| EP1911447B1 (en) | Eye drop preparation comprising xanthan gum and terpenoid | |
| SE8701479L (en) | METHOD FOR CONTAINING BIOLOGICALLY EFFECTIVE PREPARATIONS AND USE THEREOF | |
| AU732634B2 (en) | An intravenous form of thalidomide for the therapy of immunological diseases | |
| JPH08266587A (en) | Eyedrop container | |
| RU2005135133A (en) | PHARMACEUTICAL COMPOSITIONS | |
| JP2000273061A (en) | Terpenoid emulsion | |
| ATE356637T1 (en) | DRUGS CONTAINING SUPRAMOLECULAR COMPLEXES | |
| US20080093247A1 (en) | Packaging materials for formulations containing 2-pyrrolidone derivatives | |
| IL97795A0 (en) | Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles,their preparation and pharmaceutical compositions containing them | |
| JPH0448189Y2 (en) | ||
| RU94016184A (en) | Antiallergic composition for local ophthalmic use, method of its preparing | |
| JP7419565B2 (en) | Transdermal absorption formulation containing donepezil with improved stability | |
| JP2005537094A (en) | Enclosed pharmaceutical products | |
| EP0424042B1 (en) | Non-solid ophthalmic composition and process for preparing the said composition | |
| WO1998044948A3 (en) | Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties | |
| LEE et al. | Formulation influence on ocular and systemic absorption of topically applied atenolol in the pigmented rabbit | |
| WO1993018748A1 (en) | Compositions comprising a drug delivery vehicle suspended in a nonaqueous fluorinated liquid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040721 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20041210 |